Biotechnology Value Fund
San Francisco · Late Stage · 3 people tracked
Also known as BVF PARTNERS L.P.
Find your way into Biotechnology Value Fund
Team · 3 people
from public directoriesWhat they invest in
from 37 of 39 portfolio companiesBiotech ×35Healthtech ×17Medical Devices ×14AI & Machine Learning ×6Deep Tech ×6Digital Health ×3Energy ×1Enterprise Software ×1
HQs:United States×24Canada×1United Kingdom×1
Investments · 39 tracked
founders shown can be your intro pathBy year:2026 · 32024 · 62023 · 32022 · 22021 · 32020 · 32018 · 121 dated
4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases.
BiotechHealthtechEmeryville, US
David Kirn(Executive Officer, Director)inDavid Schaffer(Director)inTheresa Janke(Executive Officer)in
BoardSharon Tetlow(Director)Margi McLoughlin(Director)
Co-investorsAmzak HealthBerkeley CatalystBOLD LongevityChiesi VenturesPappas CapitalPfizer Venture Investments+3 more
Absci uses an AI-based drug creation platform combined with wet lab validation to design biologic therapeutics such as antibodies from scratch.
AI & Machine LearningBiotechDeep TechPortland, US
Sean McClain(Executive Officer)inPhil Barish(Executive Officer)inZachariah Jonasson(Chief Financial Officer and Chief Business Officer)Shelby Walker(Chief Legal Officer)inRansi Somaratne(Chief Medical Officer)Andreas Busch(Chief Innovation Officer)in
Co-investorsDas & Co.Oregon Venture FundPhoenix Venture PartnersTachyon VenturesTau VenturesCasdin Capital+2 more
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders.
BiotechHealthtechMenlo Park, US
Joseph S. Zakrzewski(Co-Founder & Director)Eric Easom(Co-Founder, President & CEO)inGeorge H. Talbot(Co-Founder & Senior Clinical Advisor)Michael R.K. (Dickon) Alley(Co-Founder, SVP Research Fellow, Head of Biology)Sanjay Chanda(Chief Development Officer)inLucy O. Day(Chief Financial Officer)in
Co-investorsAdjuvant CapitalBioRock VenturesFlucas VenturesMountain Group CapitalRA CapitalHatteras Venture Partners
AnaptysBio manages the financial collaborations from Jemperli (with GSK) and imsidolimab (with Vanda), operating a virtual model focused on protecting and returning royalty and milestone value to stockholders.
BiotechSan Diego, US
Robert Hoffman(Executive Officer)inMarco Londei(Executive Officer)inHamza Suria(Executive Officer, Director)inDaniel Faga(President, CEO, and Director)inChristopher Murphy(CFO)
BoardCarol Gallagher(Director)
Co-investorsBioBritFrazier Life SciencesNorwest Venture PartnersNovo Holdings
Black Diamond Therapeutics develops small-molecule kinase inhibitors targeting families of oncogenic mutations across cancer types, including its lead candidate silevertinib for EGFR-mutant lung cancer and glioblastoma.
Elizabeth Buck(Chief Scientific Officer)Brent Hatzis-Schoch(Chief Operating Officer and General Counsel)Sergey Yurasov(Chief Medical Officer)Melanie Morrison(Chief Development Officer)
Co-investorsLAVLilly Asia VenturesNew Enterprise Associates (NEA)Nextech InvestNSG VenturesRA Capital+3 more
Cullinan Therapeutics is a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer, with expertise in immune modulation.
BiotechHealthtechMedical Devices
Mary Kay Fenton(Chief Financial Officer)inJeffrey Jones(Chief Medical Officer)Jennifer Michaelson(Chief Scientific Officer)inCorinne Savill(Chief Business Officer)inJacquelyn Sumer(Chief Legal and Compliance Officer and Secretary)inNadim Ahmed(President and Chief Executive Officer)in
Co-investorsForesite CapitalNextech InvestOrbiMed
Foghorn Therapeutics is a clinical-stage biotech developing chromatin-targeted cancer drugs via its Gene Traffic Control platform, including a candidate co-developed with Eli Lilly.
Adrian Gottschalk(President and Chief Executive Officer)
Co-investorsFlagship PioneeringDeerfield Management Company
IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Paul Stone(Executive Officer)inYujiro S. Hata(President, Chief Executive Officer and Director)
BoardTimothy Shannon(Director)inJohn Diekman(Director)inTerry Rosen(Director)Jeffrey Stein(Director)
Co-investors5AM VenturesCanaan PartnersNextech InvestWuXi Healthcare Ventures
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Nello Mainolfi(Founder)inBruce Booth(Chair)in
Co-investorsAtlas VentureAvoro Capital AdvisorsBain Capital Life SciencesBessemer Venture PartnersHatteras Venture PartnersMRL Ventures Fund+5 more
Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance.
BiotechHealthtechSan Francisco, US
Cyrus L. Harmon, Ph.D.(Director)Cyrus Harmon(Executive Officer, Director)inCyrus L. Harmon(Director)inDavid C. Myles, Ph.D.(Executive Officer)Sean Bohen, M.D., Ph.D.(Executive Officer, Director)Naseem Zojwalla, M.D.(Executive Officer)in
Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesForesite CapitalLightspeed Venture PartnersRA CapitalLogos+1 more
ShouTi Inc. is a clinical-stage biopharmaceutical company developing oral small molecule drugs targeting G-protein coupled receptors to treat chronic diseases including obesity, type 2 diabetes, and cardiovascular conditions.
BiotechSouth San Francisco, US
Raymond Stevens(Director)Ramy Farid(Director)Jessica Lifton(Director)Ting Xie(Director)Daniel Auerbach(Director)Cuiping Gu(Director)
Co-investorsF-Prime Capital
Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications.
BiotechHealthtechMedical DevicesAustin, US
Shanshan Xu(Founder & Chief Executive Officer)inHelmut Jeggle(Co-Founder)inThang Ho(Chief Development Officer)inCrystal MacKay(Chief Operating Officer)in
Co-investorsINCE CapitalRA CapitalJanus Henderson InvestorsREDMILESalvia
Contraline develops new contraceptive and reproductive health technologies, with a focus on male contraception.
BiotechDigital HealthMedical DevicesCharlottesville, US
Kevin Eisenfrats(Co-Founder and CEO)inJohn Herr(Co-Founder)
BoardIris Van Alderwerelt van Rosenburgh(Director)Gurdane Bhutani(Director)inMartin J Emerson(Director)Tom Thorpe(Director)
Co-investorsMBX CapitalAllied Venture PartnersAmboy Street VenturesAurum Venture PartnersBeni Venture CapitalCleo Capital+14 more
Curileum develops regenerative medicine therapies targeting intestinal stem cells to prevent colorectal cancer.
BiotechHealthtechMedical DevicesLondon, GB
Dr Jeff Moore(Founder & CEO)
Co-investorsAtlas VentureCanaan PartnersProspect Venture PartnersOxford Technology Management
Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.
BiotechHealthtechMedical Devices
Co-investorsAtlas VentureForbionLightspeed Venture PartnersResearch Corporation TechnologiesTCG Crossover
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude CapitalLumira Ventures+8 more
.png)
BiotechSeattle, US
Mitchell Gold(Executive Chairman and Chief Executive Officer)inMichael Kornacker(Executive Officer, Director)inRyan Swanson(Executive Officer, Director)inDavid Miller(Executive Officer, Director)inJames Paul Rickey(Senior Vice President and Chief Financial Officer)Mark James Litton(President and Chief Operating Officer)
Co-investorsDecheng CapitalFrazier Life SciencesOrbiMed
AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.
BiotechHealthtech
Co-investorsaMoonDelos CapitalRA CapitalSoleus Capital
Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Adam Friedman(Chief Executive Officer)inAndrew Fedder(Executive Officer, Director)inBrian Piper(Executive Officer, Director)in
20260218151909.png)
Co-investorsAtlas VentureLightspeed Venture PartnersVida VenturesOmega FundsTenmileAbingworth
Aro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins.
BiotechHealthtechPhiladelphia, US
Karyn O'Neil(Executive Officer, Director)Susan Dillon(Founder)inMark V. Laurenzi(Executive Officer)
BoardElizabeth Anderson(Director)Bruce Peacock(Director)
Co-investorsAvego BioScience CapitalHealthCapAgent CapitalCowen Healthcare InvestmentsJohnson & Johnson Innovation – JJDCNorthpond Ventures
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in
BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in
Co-investorsMPM BioImpactPfizer Venture InvestmentsMirae Asset Venture InvestmentPfizer VenturesPolaris PartnersTaiho Ventures, LLC
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Chief Executive Officer, Founder)
BoardIvan Trifunovich(Director)John Wesley(Director)
Co-investors8VCAisling CapitalMission Bay CapitalMission BiocapitalOlive Tree CapitalSR One Capital Management+3 more
Eledon Pharmaceuticals is a clinical-stage biotechnology company developing immunology-based therapies, with a focus on protecting transplanted organs from rejection and treating autoimmune and neurodegenerative diseases including ALS.
AI & Machine LearningBiotechMedical Devices
Steven Perrin(President and Chief Scientific Officer)
Co-investorsJDRF T1D FundNewpath Partners
Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
BiotechDeep TechMedical Devices
David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuinAlan Saghetelian
Co-investorsNewpath PartnersCRV (Charles River Ventures)Nextech InvestRaptor GroupSamsara BioCapitalCasdin Capital+1 more
Inventiva is a clinical-stage biopharmaceutical company developing drug candidates, with a focus on liver and other diseases.
BiotechMedical Devices
Co-investorsEuropean Investment BankAndera PartnersClaret Capital PartnersNew Enterprise Associates (NEA)Samsara BioCapitalSofinnova Partners+1 more
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)inMaria Fardis(CEO)inCadmus C. Rich(Chief Medical Officer)inElaine Stracker(General Counsel)in
Co-investorsAlta PartnersCatalio Capital Management, LPDC Investment PartnersLongitude CapitalLongwood FundCatalio Capital Management+2 more
Merida is a biotherapeutics company developing a new class of drugs designed to selectively and durably eliminate the pathogenic antibodies that drive autoimmune and allergic diseases.
BiotechHealthtech
Pierre Bruhns(Co-founder; Director of Research, Pasteur Institute)Mark Shlomchik(Co-founder; Professor of Immunology, University of Pittsburgh)Michael Naill(Senior Vice President, Process and Product Development)in
Co-investorsBain Capital Life SciencesThird Rock VenturesGV (Google Ventures)
Nimbus develops wireless power technology that uses invisible infrared LED light to transmit energy across a room, with a receiver that converts the light into electricity to charge laptops, phones, and other devices.
Deep TechEnergyHardware
Michael Gorman(Founder)in
Co-investorsFoothill VenturesAccess BiotechnologyAtlas VentureBain Capital Life SciencesCommodore CapitalGV (Google Ventures)+2 more
Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.
BiotechDeep TechHealthtechSouth San Francisco, US
Cameron Pitt(Executive Officer, Director)inDerek Metzger(Executive Officer)
BoardMaha Katabi(Director)inPerry Nisen(Executive Officer, Director)inMaria Fardis(Director)inRajul Jain(Director)in
Co-investorsLongitude CapitalSofinnova VenturesVida VenturesFrazier Life Sciences
Simcha is a biotechnology company developing new cancer medicines based on immune biology research.
BiotechHealthtechNew Haven, US
Aaron Ring(Executive Officer, Director)inBeatrice McQueen(Chief Operating Officer)inSanuj Ravindran(Chief Executive Officer)Jeremy Barton(Chief Medical Director)Hirdesh Uppal(Senior Vice President Translational Research and Development Sciences)Joseph Catino(Executive Officer)
Co-investorsConnecticut InnovationsPfizer Venture InvestmentsSR One Capital ManagementAxial VCRock Springs CapitalSamsara BioCapital
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.
BiotechMedical DevicesLower Gwynedd, US
Joseph Erhardt(Executive Officer)inPeter Lebowitz(Executive Officer, Director)
BoardArjun Goyal(Director)inOtello Stampacchia(Director)inFrancesco Draetta(Director)in
Co-investorsAndreessen HorowitzVida Venturesabrdn plcForesite CapitalHillhouse InvestmentOmega Funds+1 more
Ventus AI is an enterprise automation platform offering AI agents ("AI teammates") that operate inside existing systems—desktop apps, web portals, and legacy software—without API integrations to automate complex business workflows, handling MFA, CAPTCHAs, and phone calls.
AI & Machine LearningEnterprise SoftwareHealthtechCasa Grande
Maran Vedamanikam(CEO and Manager)
Co-investorsSamsung NextAndreessen HorowitzWndrCoAlexandriaCasdin CapitalFonds de solidarité FTQ+5 more
Ventus discovers and develops small-molecule medicines using its proprietary ReSOLVE platform, focused on structure-based drug discovery.
AI & Machine LearningBiotechDeep TechHealthtechWaltham, US
Judith Lieberman(Co-Founder)Daniel Koerwer(Executive Officer)inMichael Crackower(Executive Officer)inZachary McNealy(Executive Officer)Marcelo Bigal, M.D., Ph.D.(President and Chief Executive Officer)
BoardJosh Resnick(Director)in
Co-investorsAndreessen HorowitzGV (Google Ventures)RA CapitalSoftBank Vision FundVersant VenturesCasdin Capital+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Ambrosia Biosciences Inc.Anelixis TherapeuticsIkena Oncology, Inc.Pieris PharmaceuticalsRain TherapeuticsViewPoint Therapeutics
Exits · 11
IPOs and acquisitions across the tracked portfolio4D Molecular TherapeuticsNASDAQ: FDMTAbsciNASDAQ: ABSIAN2 TherapeuticsNASDAQ: ANTXAnaptysBioNASDAQ: ANABBlack Diamond Therapeutics, IncNASDAQ: BDTXCullinan TherapeuticsNASDAQ: CGEMFoghorn TherapeuticsNASDAQ: FHTXIdeaya BiosciencesNASDAQ: IDYAKymera TherapeuticsNASDAQ: KYMROlemaNASDAQ: OLMAShouTi Inc.NASDAQ: GPCR
Portfolio news
latest coverage across their companiesOlema · investing.com · Sep 14, 2026
Nimbus · biopharmadive.com · Sep 11, 2026
Black Diamond Therapeutics, Inc · finance.yahoo.com · Sep 2, 2026
AnaptysBio · investing.com · Aug 30, 2026
Inventiva · themarketsdaily.com · Aug 26, 2026
Cullinan Therapeutics · marketbeat.com · Aug 21, 2026
AN2 Therapeutics · ng.investing.com · Aug 19, 2026
IPO stake values · per SEC filings · 6
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| AnaptysBio | 8.1% | $68.50 | Oct 2017 | $130.5M |
| Kymera Therapeutics | 5.3% | $47.00 | Jul 2021 | $123.6M |
| ShouTi Inc. | 6.8% | $15.00 | Feb 2023 | $111.2M |
| Olema | 14.3% | $19.00 | Nov 2020 | $104.5M |
| AN2 Therapeutics | 8.6% | $15.00 | Mar 2022 | $24.2M |
| Ideaya Biosciences | 5.4% | $10.00 | May 2019 | $10.5M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Public market activity · per SEC filings
what is this? ⓘ500 insider ownership filings (Forms 3/4/5)
at XOMA Royalty Corp (XOMA), Kymera Therapeutics, Inc. (KYMR), Olema Pharmaceuticals, Inc. (OLMA), MoonLake Immunotherapeutics (MLTX), IMMUNIC, INC. (IMUX), Repare Therapeutics Inc. (RPTX), ESSA Pharma Inc. (EPIX), GLYCOMIMETICS INC (CBIO)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- What stage does Biotechnology Value Fund invest at?
- Biotechnology Value Fund invests at the Late Stage stage.
- What sectors does Biotechnology Value Fund focus on?
- Biotechnology Value Fund focuses on Biotech.
- Where is Biotechnology Value Fund located?
- Biotechnology Value Fund is headquartered in San Francisco, US.
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Bessemer Venture Partners is a global venture capital firm that partners with entrepreneurs across enterprise, consumer, and healthcare sectors from early stages through growth.